A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT With Brachytherapy in Patients With Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated With Androgen Deprivation

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hafnium oxide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions
Sponsors Nanobiotix

Most Recent Events

13 Sep 2022 Results of an analysis assessing feasibility and safety from phase I trials: NCT02379845, NCT01946867, NCT02721056, NCT03589339, NCT04484909, NCT04615013 and NCT02805894 presented at the 47th European Society for Medical Oncology Congress
05 May 2021 Status changed from suspended to discontinued.
05 Apr 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Nov 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight